scholarly journals Response to letter commenting on published paper: Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis

2018 ◽  
Vol 94 ◽  
pp. 218-219
Author(s):  
Larysa H.M. Rydzewska ◽  
Sarah Burdett ◽  
Claire L. Vale ◽  
Mahesh K.B. Parmar ◽  
Jayne F. Tierney
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Androgen Deprivation Therapy ◽  
Meta Analysis ◽  
Androgen Deprivation ◽  
Hormone Sensitive ◽  
Published Paper

scholarly journals Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis

2016 ◽  
Vol 69 (4) ◽  
pp. 563-573 ◽  
Author(s):  
Marcello Tucci ◽  
Valentina Bertaglia ◽  
Francesca Vignani ◽  
Consuelo Buttigliero ◽  
Cristian Fiori ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Androgen Deprivation Therapy ◽  
Metastatic Prostate Cancer ◽  
Meta Analysis ◽  
Androgen Deprivation ◽  
Hormone Sensitive

scholarly journals Effect of Salvage Radiotherapy and Endocrine Therapy on Patients with Biochemical Recurrence After Prostate Cancer Operation— a Meta‑Analysis

2021 ◽  
Vol 15 (3) ◽  
pp. 155798832110248
Author(s):  
Yong Yuan ◽  
Qiang Zhang ◽  
Chaofan Xie ◽  
Tao Wu
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Endocrine Therapy ◽  
Androgen Deprivation Therapy ◽  
Biochemical Recurrence ◽  
Meta Analysis ◽  
Combined Treatment ◽  
Androgen Deprivation ◽  
Salvage Radiotherapy ◽  
End Point

Context: Several studies reported the application of androgen deprivation therapy and radiotherapy in patients with biochemical recurrence after prostate cancer operation. Objective: To perform a systematic review and meta-analysis evaluating of endocrine therapy and radiotherapy in patients with biochemical recurrence after prostate cancer surgery. The primary end point was biochemical progression-free survival (bPFS). Secondary end point was overall survival (OS). Methods: A systematic review of PubMed/Medline, Embase, and Cochrane databases to identify relevant studies published in English up to March 2020. Twelve studies were selected for inclusion. Results: There were 11 studies included in the present study. Including two randomized controlled trials and nine cohort studies. The meta-analysis shows a significant bPFS benefit from androgen deprivation therapy and radiotherapy in patients with biochemical recurrence after prostate cancer operation. (hazard ratio [HR]: 0.57; 95% confidence interval CI, 0.52–0.63; p < .001). For patients with GS < 7 and low-risk patients, combined treatment can have a benefit for BPFs (HR: 0.53; 95% CI, 0.37–0.76; HR: 0.58; 95% CI, 0.36–0.93). Androgen deprivation therapy and radiotherapy in patients with biochemical recurrence was associated with a slightly OS improvement (HR: 0.73; 95% CI, 0.57–0.93; p = 0.01). Conclusions: Compared with salvage radiotherapy alone, This meta-analysis shows a significant bPFS benefit from endocrine therapy combined with salvage radiotherapy in patients with biochemical recurrence after prostate cancer operation. And benefit more for high-risk groups. However, there was no significant benefit in group GS ≥ 8. It shows a slightly OS benefit from endocrine therapy combined with salvage radiotherapy in patients with biochemical recurrence.

scholarly journals Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis

PLoS ONE ◽  
2016 ◽  
Vol 11 (6) ◽  
pp. e0157660 ◽  
Author(s):  
Tobias Engel Ayer Botrel ◽  
Otávio Clark ◽  
Antônio Carlos Lima Pompeo ◽  
Francisco Flávio Horta Bretas ◽  
Marcus Vinicius Sadi ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Androgen Deprivation Therapy ◽  
Meta Analysis ◽  
Androgen Deprivation ◽  
Efficacy And Safety
Sign in / Sign up

Export Citation Format

Share Document